Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KAM

- PMLiVE

Amgen’s Blincyto effective in broader leukaemia population

Could lead to further licences for the $178,000 blood cancer treatment

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Boehringer Ingelheim headquarters

NICE U-Turn on Boehringer oncology drug

England’s drug price watchdog now recommends Vargatef for lung cancer after price cut

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links